ENXTPA:ABVXBiotechs
A Look At Abivax (ENXTPA:ABVX) Valuation After Wider Losses Trial Progress And Index Inclusion
ABIVAX Société Anonyme (ENXTPA:ABVX) is in focus after full year 2025 earnings showed revenue of €4.57 million and a net loss of €336.1 million, alongside fresh trial, leadership, financing, and index inclusion updates.
See our latest analysis for ABIVAX Société Anonyme.
The recent earnings release, positive Phase 3 safety update, leadership hires, ESOP related shelf registration, and FTSE All World Index inclusion come against a backdrop of a 1 year total shareholder return above 10x. At the...